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 ABSTRACT                                                                                                                                            
One gene, many phenotypes
Rabah M. Shawky
Pediatrics Department, Ain Shams University
Phenotype descriptions are valuable information right at the interface of medi-
cine and biology. With the rapid advancement in the fi eld of genetics, thou-
sands of genes involved in human diseases have been cloned. It was expected 
that knowledge of mutations would lead to consistent genotype-phenotype cor-
relations. The understanding of mechanisms underlying genotype-phenotype 
discrepancies is important, as it will move clinical genetics towards predictive 
medicine, allowing better selection of therapeutic strategies and individualized 
counseling of persons affected with genetic disorders.




Gene, phenotype, mosaicism, epigenet-
ics, pleiotropy.
INTRODUCTION                                
Phenotype descriptions are 
valuable information right at 
the interface of medicine and 
biology. Their main value lies 
in helping to dissect the rela-
tionships between diseases and 
genes1, in clinical application in 
genetic counseling and prenatal 
diagnosis. The phenotype can be 
thought of as a product of genes 
interacting with each other and 
with the environment. A con-
cise defi nition of a gene, taking 
into account complex patterns 
of regulation and transcription, 
genic conservation and non-
coding RNA genes, has been 
proposed by Gerstein et al.2 “A 
gene is a union of genomic se-
quences encoding a coherent set 
of potentially overlapping func-
tional products”.
Mutations in different genes can lead 
to similar phenotype e.g., hereditary 
spherocytosis can be due to mutations 
in the genes encoding for spectrin, 
ankyrin3. In contrast, mutations in one 
gene could cause multiple phenotypes, 
as best illustrated in the case of lamin 
A/C, whereby mutations can cause 13 
different diseases.4
With rapid advancement in the fi eld of 
genetics, thousands of genes involved 
in human diseases have been cloned. It 
was expected that knowledge of muta-
tions would lead to consistent genotype-
phenotype correlations, clarifying why a 
given genetic change results in a particu-
lar phenotype. However, genotype-phe-
notype correlation is often incomplete. 
Monogenic diseases provide the sim-
plest models for studying genotype-phe-
notype relationships. The understanding 
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of mechanisms underlying genotype-
phenotype discrepancies is important, 
as it will move clinical genetics towards 
predictive medicine, allowing better se-
lection of therapeutic strategies and in-
dividualized counseling of persons af-
fected with genetic disorders.5
Monogenic disease with many pheno-
types:
Ι. One gene, many mutations, many 
phenotypes:
Allelic heterogeneity.1. 
Non functional vs. partially func-2. 
tional/truncated gene product. 
Loss of function vs. gain of func-3. 
tion.
Pleiotropy.4. 
ΙΙ. One gene, one mutation, many 
phenotypes.
ΙΙΙ. Other mechanisms for phenotypic 
heterogeneity of monogenic disease:
Mosaicism (1. gene dosage effect).
Trinucleotide repeat expansion. 2. 
X- Inactivation. 3. 
Phenotypic heterogeneity due to 4. 
the interaction of alleles at different 
loci. 
Modifi er genes.5. 
Alternative splicing.6. 
Epigenetic mechanisms.7. 
Gene and environment.8. 
Ι. One gene, many mutations, many 
phenotypes.
1- Allelic heterogeneity:
This phenomenon, whereby different 
mutations at the same locus result in 
different phenotypes. It is very interest-
ing to know that mutations at a single 
locus can lead to diseases with entirely 
different clinical features. For example, 
mutations in the RET gene have been 
implicated in the etiology of Hirshprung 
disease as well as multiple endocrine 
neoplasia (MEN) Type 2. The underly-
ing mechanism is either quantitative or 
qualitative change in the gene product. 
Some of the examples of allelic hetero-
geneity have been listed in (Table 1).5
Disease Gene Disease
Huler syndrome IDUA Scheie syndrome
Charcot-marie-tooth neuropathy PMP22 Hereditary neuropathy with pressure palsy
Hyperkalemic periodic paralysis SCN4A Paramyotonia congenita
Creutzfeldt-jacob disease PRNP Familial fatal insomnia
Pseudohypoparathyroidism IA GNAS1 Albright hereditary osteodystrophy
Kennedy disease AR Androgen insensitivity
Cystic fi brosis CFTR Congenital bilateral absence of vas deference
Duchenne muscular dystrophy DMD Becker muscular dystrophy
Hirschsprung disease RET Multiple endocrine neoplasia type 2
Table 1: Selected examples of allelic heterogeneity. 5
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2- Non functional vs. partially func-
tional/truncated gene product: 
Duchenne and Becker muscular dys-
trophies are caused by mutations in the 
dystrophin gene. Mutations that par-
tially inactivate the gene product cause 
Becker muscular dystrophy (BMD), 
while mutations which completely inac-
tivate the gene product produce Duch-
enne muscular dystrophy (DMD). 
3- Loss of function vs. gain of func-
tion:
Phenotype resulting from reduction in 
the amount of normal protein is called 
loss of function, while gain of function 
mutations, also known as neomorphic, 
are characterized by the ability of the 
mutant allele product to perform new 
functions.6
Example of that is RET gene which 
codes for a tyrosine kinase receptor. 
Loss of function mutations in RET gene 
that lead to nonfunctional product or 
lower expression of RET gene give rise 
to Hirschsprung disease. Gain of func-
tion mutations at the same locus that 
produce constitutively activated recep-
tors lead to MEN Type 2. Similarly, loss 
of function mutations at FGFR1 locus 
cause an autosomal dominant form of 
Kallman syndrome characterized by 
anosmia and hypogonadotropic hypog-
onadism, also cause lacrimo-auriculo-
dento-digital (LADD) syndrome7. The 
gain of function mutations at the same 
site lead to a form of craniosynostosis 
(Pfeiffer syndrome).8
Also in the fi broblast growth factor re-
ceptor 3 (FGFR3), point mutations in 
specifi c domains are associated with 
autosomal dominant dwarfi sm and 
craniosynostosis syndromes such as 
hypochondroplasia, achondroplasia 
(the most common form of skeletal 
dysplasia), severe achondroplasia with 
developmental delay and acanthosis 
nigricans (SADDAN), thanatophoric 
dysplasia, Crouzon syndrome with 
acanthosis nigricans and Muenke coro-
nal craniosynostosis9. Several reports 
have demonstrated that these mutations 
lead to constitutive activation of the 
receptors10. In contrast with the inhibi-
tory role on bone growth, an oncogenic 
role for FGFR3 in human cancer has 
emerged. Somatic activating mutations 
in FGFR3 have been reported in mul-
tiple myeloma and, more recently, in 
two epithelial malignancies, i.e. blad-
der- and cervix carcinomas11. Nearly all 
mutations identifi ed in bladder tumours 
are identical to the activating mutations 
responsible for thanatophoric dysplasia, 
a lethal form of dwarfi sm.12
Several genes play important role 
in embryogenesis have also been 
shown to play a role in causing cancer 
(Table 2).13
Table 2: Genes that can cause both developmental anomalies and cancer.13
Gene Chromosome Developmental anomaly Cancer
PAX3 2q35 Waardenburg syndrome type 1 Alveolar rhabdomyosarcoma
KIT 4q12 Piebaldism Mast cell leukemia
PTCH 9q22 Gorlin Basal cell carcinoma 
RET 10p11 Hirschsprung MEN2A, MEN2B, thyroid carcinoma
WT1 11p13 Denys-drash Wilms tumer
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4- Pleiotropy:
The term pleiotropy comes from the 
Greek pleion, meaning “many” and tre-
pein, meaning “infl uencing”. Pleiotro-
py has been challenged by the remark-
ably diverse syndromes that can result 
from different mutations in the same 
gene, for example the LAMNA gene 
and X-linked fi lamin A gene. Mutations 
in LAMNA gene may cause Emery-
Dreifuss muscular dystrophy, a form of 
limb girdle muscular dystrophy, a form 
of Charcot-Marie-Tooth disease, dilated 
cardiomyopathy, Dunnigan type familial 
partial lipodystrophy, mandibuloacral 
dysplasia and the very rare condition 
Hutchinson-Gilford progeria. Muta-
tion in the fi lamin A gene have recently 
been implicated in the distinct, though 
overlapping, X-linked dominant dys-
morphic conditions oto-palato-digital 
syndrome, Melnick-Needles syndrome 
and frontometaphyseal dysplasia and 
periventricular nodular hetertopia.13
Antagonistic pleiotropy refers to the ex-
pression of a gene resulting in multiple 
competing effects, some benefi cial but 
others detrimental to the organism. This 
is central to a theory of aging fi rst de-
veloped by  Williams14. Williams14, sug-
gested that some genes responsible for 
increased fi tness in the younger, fertile 
organism contribute to decreased fi tness 
later in life.
One such example in male humans is 
the gene for the hormone testosterone. 
In youth, testosterone has positive ef-
fects including reproductive fi tness but, 
later in life, there are negative effects 
such as increased susceptibility to pros-
tate cancer. Another example is the p53 
gene which suppresses cancer, but also 
suppresses stem cells which replenish 
worn-out tissue.15
ΙΙ. One gene, one mutation, many 
phenotypes:
The phenomenon of allelic heteroge-
neity is not unexpected, as the gene 
product may get differentially changed 
by the different mutations and so the 
phenotypes. More surprising is the fact 
that individuals with similar genetic 
lesions can have signifi cantly differ-
ent clinical manifestations. This is well 
observed in autosomal dominant disor-
ders, where ‘variable expressivity’ and 
‘reduced penetrance’ have been classi-
cally described. Expressivity is defi ned 
as the severity of the phenotype. When 
the severity of disease differs in people 
with same genotype, the phenotype is 
said to have variable expressivity. Pene-
trance is the proportion of persons with 
a particular genotype who manifest the 
disease. The reduced penetrance leads 
to ‘skipping of generation’. Neurofi -
bromatosis Type 1(NF1) is character-
ized by extreme clinical variability, not 
only between unrelated individuals and 
among affected individuals within a 
single family but even within a single 
individual with NF1 at different times 
in life. The mutation in the NF1 gene 
can produce different lesions in differ-
ent tissues such as cafe-au-lait spots, 
neurofi broma, iris hamartoma, skeletal 
abnormalities or mental retardation. 
Each of these pleiotropic effects can 
have varying severity among the affect-
ed family members (variable expressiv-
ity). The mechanisms underlying such 
clinical variations are often unclear. It 
is supposed to be the result of the modi-
fying effects of other genes, as well as 
due to interaction with environmental 
factors.5
ΙΙΙ. Other mechanisms for phenotypic 
heterogeneity of monogenic disease:
There are a variety of other mechanisms 
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that may be responsible for generating 
phenotypic diversity of diseases that 
are encoded at a single locus, Some of 
these, which have been loosely labelled 
epigenetic, are understood, at least 
in principle, although the molecular 
mechanisms involved have not been es-
tablished and the prediction of the phe-
notype from the underlying genotype 
may be extremely diffi cult.16
1- Mosaicism (gene dosage effect):
Mosaicism is the existence of two cell 
lines with different genetic constitution 
that have been derived from a single zy-
gote.
The phenotypic severity is determined 
by the proportion of cells carrying the 
mutation. This is best exemplifi ed in 
mitochondrial disorders. There are thou-
sands of mitochondrial DNA (mtDNA) 
molecules in a cell. When a mutation oc-
curs in the mtDNA, it is at fi rst present 
in only one of the mtDNA molecules. 
At cell division, the mtDNA molecules 
replicate and sort randomly among the 
daughter cells. Each daughter cell may 
receive very different proportions of 
mitochondria carrying normal and mu-
tant mtDNA. The phenotype will de-
pend upon three factors: The relative 
abundance of mutant mtDNA (hetero-
plasmy), the tissue distribution of the 
mutant mtDNAs and the vulnerabil-
ity of each tissue to impaired oxidative 
metabolism (threshold effect). Thus, re-
duced penetrance, variable expression 
and pleiotropy are typical features of 
kindred with mitochondrial disorders. 
For example, a deletion of 4977 bp of 
mtDNA is commonly encountered in 
Kearns-Sayre syndrome (characterized 
by the triad of pigmentary retinopathy, 
external ophthalmoplegia and onset be-
fore the age of 20 years). The same de-
letion has also been identifi ed in cases 
of Pearson syndrome (sideroblastic 
anemia, exocrine pancreatic dysfunc-
tion) and progressive external ophthal-
moplegia. The different phenotypes 
from the same deletion are due to tissue 
distribution of the defect. If the defect 
is present in mitochondria of all tissues, 
the phenotype is Kearns-Sayre syn-
drome. In Pearson syndrome, the defect 
is localized mainly to the hematopoietic 
tissue, while the defect is confi ned to 
the skeletal tissues in progressive exter-
nal ophthalmoplegia17. Another striking 
example of phenotypic diversity arising 
from mosaicism is the androgen insen-
sitivity syndrome (AIS). Androgen in-
sensitivity syndrome is the major cause 
of male pseudohermaphroditism. It is 
an X-linked disorder caused by muta-
tions in androgen receptor (AR) gene. 
Androgen insensitivity syndrome can 
be subdivided into three highly variable 
phenotypes: complete AIS, when the 
affected persons have female external 
genitalia; partial AIS, when the genita-
lia are ambiguous and mild AIS, when 
the affected individuals have normal 
male external genitalia. In a number of 
cases, identical mutations have resulted 
in signifi cantly different phenotypes. 
This is due to somatic mosaicism18. The 
co-expression of wild allele shifts the 
AIS subtype to a higher degree of viril-
ization than expected from the mutant 
allele alone.5
2- Trinucleotide repeat expansion:
Also known as triplet repeat expansion, 
is the DNA mutation responsible for 
causing any type of disorder categorized 
as a trinucleotide repeat disorder. These 
are labelled in dynamical genetics as 
dynamic mutations19. At least 12 neu-
rological diseases are known to result 
from expansion of CTG, CGG, CAG 
or GAA repeats. Fragile-X syndrome, 
which is a common cause of mental re-
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tardation in males, is a good example of 
how phenotypic, heterogeneity can be 
generated by expansion of regions con-
taining trinucleotide repeats, in normal 
individuals, a DNA segment at Xq27,3 
contains between six and 60 copies of 
the repeat CGG, in some persons, the 
number is increased to between 60 and 
200. In this case, the disorder is clini-
cally silent; premutations of this kind 
are characteristic of normal-transmit-
ting males and some mentally normal 
female carriers. Full mutations, which 
arise in the offspring of pre-mutation 
carriers, consist of many hundreds or 
thousands of copies, of the repeat and 
lead to the full expression of the clini-
cal phenotype. Heterozygous carriers 
have an extremely variable pheno type: 
Approximately 50% of females carry-
ing the full mutation, how some mental 
impairment although those who carry a 
pre-mutation are usually normal. Simi-
larly, female carriers may or may not 
show some of the somatic changes as-
sociated with the disease in males. Al-
though X inactivation may be partly 
responsible, this does not seem to be 
the whole story. Huntington’s disease, 
another neurodegenerative dis order, 
also shows considerable phenotypic 
heterogeneity, particularly with respect 
to age of onset and rate of progression, 
At the 5`- region of the locus involved 
there is a CAG repeat sequence, which 
ranges from ten to 30 copies in normal 
individuals and which is expanded to 
beyond 35 copies in patients with Hun-
tington’s disease, there appears to be 
some relationship between the length of 
the repeats and age of onset. Remark-
ably, the juvenile onset of cases shows 
a preponderance of paternal trans-
mission16. In 2007 a new disease model 
was produced to explain the progression 
of Huntington’s Disease and similar 
trinucleotide repeat disorders, which, 
seems to accurately predict age of onset 
and the way the disease will progress in 
an individual, based on the number of 
repeats of a genetic mutation20. Over-
all these conditions show considerable 
phenotypic heterogenity This is refl ect-
ed at the molecular level, where there 
is a wide variation in the extension of 
the length of the repeats required to 
produce an abnormal phenotype, not all 
diseases are associated with a premuta-
tion length and the relationship between 
the expan sion of trinucleotide repeats 
and the causation of the disease is not 
clear. In some cases, those in which the 
repeats involve promoters, it is thought 
that methylation of the promoter region 
lead to gene silencing while in those 
that involve CAG repeats it is thought 
that polyglutamine expansion may play 
a role. But what is clear is that genotyp-
ic instability of this type is responsible 
for neurodegenerative disorders with 
widely differing phenotypes.16
3- X- Inactivation:
X-inactivation in females is usually 
random, because of that female carriers 
for a particular X-linked trait are in ef-
fect, mosaics, with each cell population 
functionally hemi zygous for a particu-
lar trait. Hence carriers would be ex-
pected to produce approximately half 
of an abnormal gene product or express 
about the same amount of a product. 
However, because X inactivation oc-
curs early during embryogenesis, there 
is wide variation in the expression of 
X-linked mutant genes in females; con-
siderable skewing of the distribution 
of values is encountered. Interestingly, 
there is a high frequency of discor-
dant phenotypes, among twins with X-
linked diseases21, this may be because 
X inac tivation preceeds twinning  and 
non-randomness refl ects asymmetri-
cal splitting of the inner cell mass, 
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furthermore, it seems likely that some 
X-linked disorders may have a deleteri-
ous effect on cell function during early 
embryogenesis, a phenomenon that may 
lead to extreme skewing of the distribu-
tion of cell populations. The situa tion 
is further complicated by the fact that 
not all parts of the X chromosome are 
inactivated. These different issues make 
for considerable hetero geneity in the 
expression of mutant gene’s in female 
carriers for X-linked disorders. There 
is increasing evidence that negative 
selection may be a major factor for the 
skewed distribution of cell populations 
in female carriers. For example, Cole-
man et al.22 described a female with the 
genes for both incontinentia pigmenti 
and haemophilia A. It appeared that the 
presence of the gene for incontinentia 
pigmenti on an X chromosome had un-
masked the factor VIII gene mutation 
on the other chromosome, presumably 
by negative selection of the former. 
Another example is female carriers of 
hemophilia and  DMD may occasion-
ally show mild or even full expression 
of the disease. This is due to nonran-
dom inactivation of X chromosome, as 
by chance, most of the X chromosomes 
carrying the normal allele get inactivat-
ed resulting in clinical expression of the 
disease.5
4- Phenotypic heterogeneity due to 
the interaction of alleles at different 
loci: 
Retinitis pigmentosa is the name given 
to a set of inherited degeneration of the 
retina. This condition is very heteroge-
neous, both clinically and with respect 
to inheritance. It is X- linked, however 
both autosomal dominant and recessive 
forms have been described. Kajiwara 
et al.23  reported three families in which 
a form of retinitis pigmentosa segre-
gated; affected individuals were double 
heterozygotes for a specifi c peripherin-
RDS gene muta tion and a muta tion in a 
second gene, ROM1. It is thought that 
the products of these two loci. which 
are on different chromosome, interact 
non-convalently in the rim region of the 
photoreceptor outer segment disc mem-
brane. Persons heterozygous for only 
one of these muta tions have no symp-
toms.
Another condition that shows marked 
phenotypic heterogeneity is inher-
ited porphyria cutanea tarda. in which 
heterozygotes are predisposed to pho-
tosensitive cutaneous lesions. The phe-
notype seems to be exacer bated by a 
variety of enviromental factors, includ-
ing iron overload and alcohol abuse. 
The condition results from a defi ciency 
of uroporphyrinogen decarboxylase 
(URO-D). Not all patients with muta-
tions at the gene that encodes URO-D 
are symptomatic. Recently it has been 
found that there is an increased frequen-
cy of the alleles of the haemochromato-
sis gene, notably C282Y AND H63D, 
in both Argentinian and Italian patients 
with porphyria culanea tarda. Since the 
haemochromatosis alleles are associ-
ated with increased iron absorption and 
iron overload and because iron loading 
exacerbates porphyria cutanea tarda, 
it seems likely that this is another ex-
ample of the deleterious interaction of 
two alleles, in this case with completely 
different functions.24,25
5- Modifi er genes:
A modifi er gene is defi ned as an inher-
ited genetic variation that affects the 
phenotypic expression of another gene. 
It can affect the pleiotropy, penetrance 
or expressivity of the disease. Depend-
ing upon the nature of modifying effect, 
modifi er genes might cause more severe 
phenotypes, less severe phenotypes, 
novel phenotypes or wild-type (normal) 
phenotypes.26 
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A- Modifi er causing less severe (re-
duced) phenotype of Beta thalassemia.
The severity of anemia in beta thalas-
semia refl ects the degree of globin 
chain imbalance. The excess of alpha 
globin chain precipitates in red cell pre-
cursors leading to ineffective erythro-
poiesis. This imbalance can be geneti-
cally modifi ed by two factors-variation 
in amount of gamma globin response 
and alpha globin chain production27. 
The beta thalassemia patients who co-
inherit alpha globin gene deletions will 
have less redundant alpha globin chains 
and tend to have less severe phenotype. 
Similarly, increased synthesis of gam-
ma globin chain will reduce the disease 
severity by increasing HbF level. The 
gamma globin response is also geneti-
cally determined. There are many other 
loci that are not linked to the beta globin 
gene but modify HbF response. Linkage 
studies have mapped these loci to three 
regions of the genome-chromosome 
6q23, 8q11 and Xp22.28
B- Modifiers causing more 
severe (enhanced) phenotype 
The severity of anemia in beta thalas-
semia depends on the degree of globin 
chain imbalance. It is an autosomal re-
cessive condition. The heterozygotes 
for beta thalassemia mutations are clini-
cally asymptomatic as the degree of im-
balance is insignifi cant. But, the coin-
heritance of extra alpha globin genes 
(alpha triplication) increases the imbal-
ance. This leads to symptomatic disease 
in heterozygotes, sometimes manifest-
ing as ‘intermedia’ phenotype.29
6- Alternative splicing:
Alternative mRNA splicing is another 
mechanism responsible for different 
expression of a similar genotype. Two 
illustrative examples are given below.
A- Duchenne muscular dystrophy and 
BMD are caused by mutations in the 
dystrophin gene. Duchenne muscular 
dystrophy is a severe muscle-wasting 
disease arising from defects in the 
dystrophin gene, typically nonsense 
or frameshift mutations that preclude 
the synthesis of a functional protein. 
Becker muscular dystrophy generally 
arises from in-frame deletions that al-
low synthesis of a shorter but still semi-
functional protein. But, nonsense muta-
tions which should cause DMD have 
been reported in BMD. This is due to 
alternative mRNA splicing- skipping of 
the affected exon leads to removal of 
the nonsense mutation from the dystro-
phin mRNA. This results in production 
of partially functional dystrophin and 
BMD phenotype.
B- Cystic fi brosis is an autosomal re-
cessive disorder. The genotype delta 
F508/R117H can lead to either severe 
phenotype of cystic fi brosis leading to 
respiratory failure or the milder pheno-
type, in which the only manifestation is 
congenital bilateral absence of vas def-
erens (CBAVD). The CFTR gene has 
two intron 8 variants. One is associated 
with effi cient mRNA splicing, while the 
other causes ineffi cient splicing. The 
R117H allele is capable of producing 
partially functional protein. The R117H 
allele associated with effi cient splicing 
leads to production of some amount of 
partially functional protein and hence 
milder phenotype (CBAVD). On the 
other hand, severe phenotype results if 
the intron 8 variant causes ineffi cient 
splicing and production of nonfunction-
al protein.30
7- Epigenetic mechanisms:
The term epigenetics refers to changes 
in gene expression caused by envi-
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ronmental factors, not by changes in 
the underlying DNA sequence. These 
changes may remain through cell divi-
sions for the remainder of the cell’s life. 
Sometimes the changes last for multiple 
generations31. The Greek prefi x epi- in 
epigenetics implies features that are “on 
top of” or “in addition to” genetics; thus 
epigenetic traits exist on top of or in ad-
dition to the traditional molecular basis 
for inheritance. Epigenetic phenomena 
modulate when and at what level genes 
are expressed. Thus, the expression of a 
mutation also depends upon the activity 
state of the locus carrying it; the mere 
presence of a genetic defect may not be 
enough for clinical expression. Epige-
netic effects in humans include the fol-
lowing:
A- Genomic imprinting and related 
disorders:
The term “imprinted gene” refers to 
genes whose expression is conditioned 
by their parental origin.32
The expression of a gene depends upon 
the parent who passed on the gene. 
For example, two different diseases 
- Prader-Willi syndrome and Angelman 
syndrome - are due to deletion of the 
same part of chromosome 15. When the 
deletion involves the chromosome 15 
inherited from the father, the child has 
Prader-Willi syndrome, but when the 
deletion involves the chromosome 15 
inherited from the mother, the child has 
Angelman syndrome. This is a striking 
example of how the parental origin of 
a genetic defect infl uences the clinical 
phenotype. Beckwith-Wiedemann syn-
drome is also associated with genomic 
imprinting, often caused by abnormali-
ties in maternal genomic imprinting of 
a region on chromosome 11.
B- Transgenerational epigenetic ob-
servations:
Marcus Pembrey and colleagues also 
observed that the paternal (but not ma-
ternal) grandsons of Swedish boys who 
were exposed to famine in the 19th cen-
tury were less likely to die of cardiovas-
cular disease; if food was plentiful then 
diabetes mortality in the grandchildren 
increased, suggesting that this was a 
transgenerational epigenetic inheri-
tance.33
8- Gene and environment:
Virtually all human diseases result from 
the complex interplay of genetic sus-
ceptibility factors and modifi able envi-
ronmental factors. This is most obvious 
in the context of common illnesses such 
as diabetes, coronary artery disease or 
cancer. But, environmental factors play 
a signifi cant role in the expression of 
monogenic disorders too. For example, 
inherited metabolic disorders manifest 
when there is introduction of the sub-
strate for which the metabolism is de-
fective. Similar genetic defects may 
have different phenotypes if the envi-
ronmental factors are not similar.5
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